Characteristics and outcomes of patients hospitalized for heart failure in the United States: Rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE)Kirkwood F. Adams, Darlene P. Horton, Gregg C. Fonarow et al.|American Heart Journal|2005Cited by 2.1k
Intravenous Nesiritide, a Natriuretic Peptide, in the Treatment of Decompensated Congestive Heart FailureWilson S. Colucci, Thierry H. LeJemtel, Uri Elkayam et al.|New England Journal of Medicine|2000Cited by 908
Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: The PRECEDENT studyAndrew J. Burger, Uri Elkayam, Darlene P. Horton et al.|American Heart Journal|2002Cited by 323
Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failureRoger M. Mills, Kanu Chatterjee, Thierry H. LeJemtel et al.|Journal of the American College of Cardiology|1999Cited by 323
Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of patients with acutely decompensated heart failureMarc A. Silver, Uri Elkayam, Darlene P. Horton et al.|Journal of the American College of Cardiology|2002Cited by 232